view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Watch on YouTube
Vox Markets speaks to Mo Khan, CEO of clinical research specialist Hvivo, about a new $2.5 million contract for an Omicron variant study to determine the virus dose needed to infect vaccinated individuals. This study will facilitate future human challenge trials to test vaccines and antivirals, with significant developments expected in 2025, expanding H Vivo’s market opportunities.
The Vox Markets Podcast